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A strongly electronegative, bay-region analogue of the potent
carcinogen 15,16-dihydro-ll-methylcyclopenta[a]phenan-
thren-17-one, namely 15,16-dihydro-ll-trifluoromethykyclo-
penta[a]phenanthren-17-one, is mutagenk to Salmonella
typhimurium TA100. Also it is metabolized at the 1,2- and
3,4-positions in the A-ring as well as C-15 in the D-ring to
give 3,4-dihydroxy-3,4,15,16-tetrahydro-ll-trifluoromethyl-
cyclopenta[a]phenanthren-17-one as the only mutagenk
metabolite. In these respects its behaviour is closely similar
to that of the 11-methyl compound, suggesting that the
electronic nature of the bay-region substituent is rather less
critical than its spatial configuration in influencing metabolism
to genotoxic intermediates. It remains to be seen, however,
whether the trifluoromethyl compound is also a carcinogen.
15,16-Dihydrocyclopenta[a]phenanthren-17-one (1, cpp-17-one*)
(Figure 1), the parent 17-ketone of the 15,16-dihydrocyclo-
penta[a]phenanthrene (cpp) series, is devoid of intrinsic carcino-
genicity (1); however, substitution of a methyl group at C-ll
(Figure 1) confers considerable carcinogenic activity on the
molecule (2). This 11-methyl derivative (2) has been found to
induce skin tumours in a number of mouse strains (1 -5 ) as well
as a variety of other soft tissue tumours following s.c. injection
in rats and mice (2,3,6). More recently it has been observed to
increase the rate of myeloid leukaemia in male Sprague -Dawley
rats; in addition the compound was found to act as a potent
initiator of silica-induced mesothelioma (7). The carcinogenicity
of cpps is believed to be mediated through metabolic activation
to bay-region diolepoxides (2,8). It was therefore of interest to
examine whether it is the steric or electronic effects of the
11-methyl group that influence the activation of the compound
to reactive intermediates. It was decided to synthesize an analogue
of 1 l-CH3-cpp-17-one (2) possessing a group at C-l 1 which was
spatially similar to methyl, yet electronically very different. The
most appropriate candidate for this replacement was considered
to be trifluoromethyl, due to the similarity in size of hydrogen
and fluorine (van der Waals radii H = 1.2 A; F = 1.35 A),
but their very different affinities for electrons (H = 0.8 eV;
F = 3.448 eV, in the gas phase at OK) (9). Consequently the
11-trifluoromethyl derivative (3) was synthesized (10), and its
in vitro metabolism has now been examined and the identities
of the principal metabolites determined. Moreover the compound
and its metabolites have been tested for activity in the Ames
mutagenicity assay
The 11-trifluoro-17-ketone (3) was metabolized and the
metabolites separated by HPLC as previously described (11),
using hepatic microsomal preparations from rats pretreated with
Aroclor 1254 (prepared as outlined in ref. 12). The principal in
vitro metabolites were tentatively identified on the basis of
retention times on HPLC coupled with UV absorption spectra.
Previous experience (2,13) has shown that the positions of
saturation in the aromatic rings (and hence the positions of the
hydroxyl groups) can be unambiguously assigned from their UV
chromophores, especially since in each case simple in situ
reduction of the carbonyl group produces a second, highly
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Fig. 1. Structures of compounds 1-3, and the major metabolites of the
11-trifluoromethyl-17-ketone (3).
Injection
•Abbreviations: cpp-17-one, 15,16-dihydrocyclopenta[a]phenanthren-17-one.
Other derivatives of 15,16-dihydrocyckjpenta[a]phenanthrene (cpp) are similarly
abbreviated.
Fig. 2. HPLC profile of the in vitro metabolites of 15,16-dihydro-ll-tri-
fluoromethylcyclopenta[a]phenanthreri-17-one. Metabolism was carried out as
previously described. Trace monitored by UV absorption at 254 run.
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TaWe I. Mass spectral data of peaks 1 - 5
Peak Predicted
mol. wt
mil (% relative abundance) and
probable fragments) lost
mlz of molecular km of TMS
derivative
5
4
3
2
1
C18HUOF3
M, 300
C.nH.AFj
M, 316
C18H13°3F3
M, 334
C18H13O3F3
M, 334
M, 350
300 (100), M; 272 (7), M-CO; 231 (11)
M-CF3; 203 (91), M-CO-CF3
316 (100), M; 298 (45), M-H20; 288
(11), M-CO; 270 (47), M-H2O-CO; 251
(50), M-H2O-CO-F; 247 (11), M-CF3;
229 (16), M-H2O-CF3; 219 (18), M-CO-CF3
334 (13), M; 316 (100), M-H20; 288
(80), M-H2O-CO; 287 (12), M-H2O-CHO;
259 (13), M-H2O-CO-CH0; 219 (52), M-
H2O-CO-CF3
334 (19), M; 316 (43), M-H2O; 288
(100), M-H2O-CO; 287 (9), M-H2O-CHO;
259 (11), M-H2O-CO-CH0; 219 (34), M-
H2O-CO-CF3
350 (16), M; 332 (30), M-H20; 314 (31),
M-2H2O; 304 (49), M-H2O-CO; 286 (43),
M-2H2O-CO; 258 (21), M-2H2O-2CO;
189 (100), M-2H2O-2CO-CF3
388
(one OH group)
478
(two OH groups)
478
(two OH groups)
566
(three OH groups)
characteristic chromophore. These identities were then verified
by 70 eV electron impact mass spectrometry using a VG Quattro
instrument; the metabolites were dissolved in ethyl acetate for
direct insertion, and later derivatized by addition of trimethylsilyl
imidazole (Aldrich, product no. 15 358—3) to the solution for
a few minutes at room temperature before reinsertion. Mutagenic
potential was determined in the Ames test (14) using Salmonella
typhimurium TA100 as previously described (11)
Incubation of ll-CF3-cpp-17-one (3) with microsomal
preparations from Aroclor 1254-treated rats revealed the presence
of five major peaks which were absent from blank microsomal
preparations (Figure 2). Peak 5, being the least polar compound
present, was unchanged ll-trifluoromethyl-cpp-17-one (3)
identified by its retention time and UV absorption spectrum
0^271, 300, 354, 371; after BH,- 259 run—italics indicate
peaks of highest intensity). Peak 4 was assigned the structure
of a D-ring mono-ol since it was observed to be somewhat more
polar than the parent compound (peak 5), and its UV spectrum
was very similar (X,^ 275, 300, 357, 374; after BH4- 258 nm)
as expected, since they possess the same chromophore. It is
thought likely that the compound was in fact the 15-hydroxy
derivative since 15-ols have been found as major metabolites of
other cpp-17-ones (2). Peak 3 was found to inhabit the region
of the chromatograph usually occupied by a diequatorial
3,4-dihydrodiol and this was confirmed by its UV absorption
characteristics (Xmax 268, 331; after BH," 246, 323 nm).
Peaks 1 and 2 were observed to elute at HPLC areas usually
inhabited by the diaxial 1,2-<lihydrodiols and 1,2,15-triols, and
their structures were again established by their ultraviolet spectra
(peak 1, XmflX234, 272, 334; after BH," 257, 265, 311 nm;
peak 2, X ^ 233, 265, 331; after BH," 258, 266, 310 nm).
Since peak 1 was rather more polar than peak 2 it was considered
likely that peak 2 was the 1,2-dihydrodiol, while peak 1 was the
1,2,15-trihydroxy derivative found as a major metabolite of other
cpp-17-ones (2). All these retention times were closely similar
to those of the corresponding metabolites derived from the
11-methyl compound, in these cases known to be trans. These
tentative identifications were confirmed by MS (Table I) which
showed that the metabolites' mol. wts and major fragments were
consistent with the proposed structures (see Figure 1). Moreover,
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Fig. 3. Activation of ll-CF3<pp-17-one (3) and 3,4-<Uhydroxy-ll-CF3<pp-
17-one to mutagens by hepatic microsomal preparations from rats pretreated
with Aroclor 1254. Spontaneous reversion rate was 81 ± 12. Figures are
presented as mean±SD. Neither compound was mutagenic in the absence of
an hepatic microsomal activation system.
Mstabodc fraction
Fig. 4. Mutagenkity of the principal compounds separated by HPLC
following in vitro metabolism of ll-CF3-cpp-17-one. All compounds tested
at 7 jig/plate using a 10% (v/v) microsomal activation system prepared from
the livers of rats pretreated with Aroclor 1254. Spontaneous reversion rate
was 87±9. Figures are presented as mean±SD.
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Activation of the 11-trtfluoromethyl analogue of cpp-17-one
after treatment with trimethylsilyl imidazole in order to convert
hydroxyl residues to their trimethylsilyl ethers, in each case the
molecular ion was in accord with the expected number of OH
groups.
The 1 l-trifluoro-17-ketone (3) was examined in the Ames test
using Salmonella typhimurium TA100 and a 10% (v/v)
microsomal activation system utilizing microsomes from rats
pretreated with Aroclor 1254 (Figure 3). Since the compound
was found to be mutagenic only after metabolic activation, it was
decided to ascertain which of the in vitro metabolites were
involved in its mutagenicity. The five principal peaks present after
in vitro metabolism were collected and put into solution in DMSO
at 100 /ig/ml. Each was tested, with metabolic activation, at
7 /tg/plate, the most mutagenic concentration of ll-CF3-cpp-17-
one (Figure 3). Only peak 5 [11-CF3- cpp-17-one (3)] and peak
3 (the 3,4-dihydrodiol) were found to be mutagenic (Figure 4).
To confirm the mutagenicity of the 3,4-dihydrodiol (peak 3) the
assay was repeated at four concentrations of the compound
(Figure 3), giving a good dose-response relationship.
Thus the in vitro metabolism of 15,16-dihydro-ll-trifluoro-
methylcyclopenta[a]phenanthren-17-one (3) by hepatic micro-
somal preparations resulted in the production of four principal
metabolites (Figure 1) identified as 15,16-dihydro-15-hydroxy-
ll-trifluoromethylcyclopenta[a]phenanthren-17-one (peak 4),
3,4-dihydroxy-3,4,15,16-tetrahydro-l 1-trifluoromethylcyclo-
penta[a]phenanthren-17-one (peak 3), l,2-dihydroxy-l,2,15,
16-tetrahydro-1 l-trifluoromethylcyclopenta[a]phenanthren-17-
one (peak 2) and l,2,15,16-tetrahydro-l,2,15-trihydroxy-ll-
trifluoromethylcyclopenta[a]phenantnren-17-one (peak 1). Thus
the ll-trifluoromethyl compound (3) is metabolized in a
qualitatively similar manner to its 11-methyl analogue (2) (15)
in that metabolism occurs at two sites on the A-ring and at one
of two positions on the D-ring. Although the metabolism proceeds
in a qualitatively similar manner, in terms of the major meta-
bolites produced, to that of ll-CH3-cpp-17-one, the overall
metabolic profile of the 11-trifluoromethyl compound (3) is
simpler (Figure 2). Metabolism of the 11-memyl compound (2)
produces a more complex pattern of minor metabolites such as
the 16-ol and 11-hydroxymethyl compound and their A-ring
derivatives (2) which are largely absent in the metabolism of its
II-CF3 analogue.
The activation of ll-CF3-cpp-17-one (3) to genotoxic
intermediates appears to proceed via the 3,4-dihydrodiol since
this was the only metabolite found to be mutagenic (Figures 3
and 4) and moreover was observed to be a more potent mutagen
than the parent compound. The cpp-17-ones are considered to
exert their observed genotoxicity through a bay-region
3,4-diol-l,2-epoxide (2) and it is known that this reactive
intermediate is generated from the parent compound via the
3,4-dihydrodiol which is more mutagenic than the parent
compound (2,11). Thus it appears that ll-CF3-cpp-17-one (3)
is activated to genotoxic species in an entirely analogous manner
to its 11-methyl analogue (2). The electronic nature of the -CF3
substituent at C-l 1 is radically different from that of the -CH3
group that it mimics, yet qualitatively similar metabolism occurs
especially in the apparent activation of the compound to
genotoxins. Given the apparent similarity of the metabolism and
activation of ll-CH3-cpp-17-one (2) and its 11-CF3 analogue
(3), it would appear that the electronic nature of the substituent
at C-l 1 is not vital in determining whether or not the compound
is activated to genotoxic intermediates; consequendy the more
important effect of the substituent at C-l 1 would appear to be
steric. Whether the electronic nature of the substituent at C-l 1
affects the carcinogenicity of the molecule is a question that cannot
be addressed through the medium of uiese metabolic studies and
must therefore await the results of longer term tumorigenicity
experiments.
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